



Form	PTO-1449	Modified

List of Patent and Publications Cited by Applicant (Use several sheets if necessary)

U.S. Department of Commerce Patent and Trademark Office

Docket	No.
CRD50	68USNP

Application No. 10/796,397

Applicant Robert Falotico, et al.

Filing Date March 9, 2004

Group 1615

Confirmation No. 1881

## **U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
/CH/	1	3,929,992	12/30/75	Seghal et al.	424	122
1	2	3,959,078	05/25/76	Guire	530	350
	3	4,350,160	09/21/82	Kolesov et al.	227	179.1
·	4	4,366,819	01/04/83	Kaster	606	153
	5	4,368,736	01/18/83	Kaster	606	153
	6	4,624,257	11/25/86	Berggren et al.	606	153
	7	4,722,906	02/02/88	Guire	436	501
	8	4,733,665	03/29/88	Palmaz	606	108
	9	4,739,762	04/26/88	Palmaz	623	1.11
	10	4,776,337	10/11/88	Palmaz	623	1.11
	11	4,917,090	04/17/90	Berggren et al.	606	153
	12	4,917,091	04/17/90	Berggren et al.	606	153
	13	5,229,172	07/20/93	Cahalan et al.	427	536
·	14	5,234,447	08/10/93	Kaster et al.	606	153
	15	5,308,641	05/03/94	Cahalan et al.	427	2.1
	16	5,350,800	09/27/94	Verhoeven et al.	525	54.2
	17	5,415,938	05/16/95	Cahalan et al.	428	409
	18	5,837,313	11/17/98	Ding et al.	427	2.21
	19	6,099,562	08/08/00	Ding et al.	623	1.46
	20	6,120,536	09/19/00	Ding et al.	623	1.43
A	21	6,153,252	11/28/00	Hossainy et al.	427	2.3
/CH/	22	6,425,898	07/30/02	Wilson et al.	606	108

	<del></del>		
EXAMINER	/Casey Hagopian/	DATE CONSIDERED	08/19/2007

Form PTO-1449 Modified				Docket No. Application No. CRD5068USNP 10/796,397		
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office			Applicant Robert Falotico, et al.			
			Filing Date March 9, 2004	Group 1615		
			Confirmation No. 1881			
		FORI	EIGN PATI	ENT DOCUMENTS		
Examiner Initial		Document No.	Date	Country	Transla YES	tion NO
/CH/	23	10127011 A1	12/12/02	DE	X	
1	24	02/064127 A1	08/22/02	wo		
	25	03/020331 A1	03/13/03	wo	X abstract	
$\overline{}$	26	03/034944 A1	05/01/03	wo	X abstract	
/CH/	27	2005/016187 A1	02/24/05	WO		
			1			
<u> </u>	-		<u> </u>			
<u></u>						
	<del> </del>		<del> </del>		_	
			1			
				,		

EXAMINER	/Casey Hagopian/	DATE CONSIDERED	08/19/2007	
				@ 2006 WW

<u> </u>	Form PTO-1449 Modified  List of Patent and Publications  Cited by Applicant  (Use several sheets if necessary)		Docket No. CRD5068USNP	Application No. 10/796,397	
			Applicant Robert Falotico, et al.		
			nent of Commerce Frademark Office	Filing Date March 9, 2004	Group 1615
				Confirmation No. 1881	
	NON	-PAT	ENT DOCUMENTS (I	ncluding Author, Title, l	Date, Pertinent Pages, Etc.)
/Cł	H/	28		oroelastomers-dependence IER, 1989, 30, 2180-2187	of relaxation phenomena on
	1.	29	Berk, B. C. et al., "Hep Cardiol., 1991, 17, 111		s Inhibit Restenosis," J. Am. Coll.
		30	Beutler, E., "Cladribine (2-chlorodeoxyadenosine)," Lancet, 1992 Oct 17, 340(8825 952-956		
		31	Brehm, B. R. et al., "Beta-blockers of the third generation inhibit endothelin-1 liberation, mRNA production and proliferation of human coronary smooth muscle and endothelial cells," J Cardiovasc Pharmacol, Nov. 2000, 36(5 Suppl 1), S401-S403		
		32		or system in vitro and in v	nelin-1 concentrations modulate the ivo," J Cardiovasc Pharmacol. Nov.
-	-	33		e," In: Vascular Smooth I	ic Modulation of Smooth Muscle  Muscle in Culture, Vol. 1, Ch. 4,
		34	Campbell, G. R., et al., "Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis," Exp. Mol. Pathol., April 1985, 42(2), 139-162		
		35	Carrera, C. J. et al., "Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy," J. Clin. Invest, 1990 86(5), 1480-1488		
,	1	36	Carson, D. A. et al., "DNA strand breaks, NAD metabolism, and programmed cell death," Exp Cell Res, 1986 Jun, 164(2), 273-281		
/CH	1/	37		enetic analysis of deoxya p Med Biol, 1986, 195 Pt	denosine toxicity in dividing human B, 207-211

EXAMINER	/Casev Hagopian/	DATE CONSIDERED	08/19/2007
			@ 2004 WW

Form	List of Patent and Publications Cited by Applicant		Docket No. CRD5068USNP	Application No. 10/796,397
			Applicant Robert Falotico, et al.	
		nent of Commerce Frademark Office	Filing Date March 9, 2004	Group 1615
			Confirmation No. 1881	
NON	-PAT	ENT DOCUMENTS (In	cluding Author, Title, Date	, Pertinent Pages, Etc.)
/CH/	38			ONA damage by toxic oxygen , 1986 Mar 1; 163(3), 746-751
	39	methylthioadenosine and	etabolism to methionine and I 5'-methylthioinosine in mai 1983 Apr 29, 112(2), 391-39	nmalian cells," Biochem
	40		ecific toxicity of 2-chlorodec phocytes," Blood, 1983 Oct,	exyadenosine toward resting and 62(4), 737-743
	41	Chang, M. W. et al., "Ac dependent," J. Clin. Inve		pression of the Cyclin/Cyclin-
	42		inetics of cellular proliferation of muscle mitogenesis and r	on after arterial injury. IV. nigration," Circ. Res., 1986,
	43		inetics of cellular proliferationscle growth by heparin," Lab	on after arterial injury. II. . Invest., 1985, 52(6), 611-616
	44		gnificance of quiescent smoon of Circ Res. 1985, 56(1), 139	
	45	Clowes, A. W., "Suppression by heparin of smooth muscle cell proliferation in injured arteries," Nature, 1977, 265(5595), 625-626		
	46	Colburn, M. D. et al., "Dose responsive suppression of myointimal hyperplasia by dexamethasone," J. Vasc. Surg., 1992, 15, 510-518		
<u> </u>	47	Currier, J. W. et al., "Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit," Supplement To Circulation, 1989, 80(4), Abstract No. 0263		
/CH/	48		listone deacetylases inhibitorial growth factor signaling,	rs as anti-angiogenic agents 'Oncogene, 2002, 21 (3), 427-

EXAMINER	/Casey Hagopian/	DATE CONSIDERED	08/19/2007	

	List of Patent and Publications Cited by Applicant		Docket No. CRD5068USNP	Application No. 10/796,397	
			Applicant Robert Falotico, et al.		
			nent of Commerce Frademark Office	Filing Date March 9, 2004	Group 1615
				Confirmation No. 1881	
	NON	-PAT	ENT DOCUMENTS (In	cluding Author, Title, Date,	Pertinent Pages, Etc.)
/	CH/	49	Edelman, E. R. et al., "P. 81(7A), 4E-6E	athobiologic responses to ste	nting," Am J. Cardiol. 1998,
		50	Farb, A. et al., "Vascular smooth muscle cell cytotoxicity and sustained inhibition on neointimal formation by fibroblast growth factor 2-saporin fusion protein," Circ. Res., 1997, 80, 542-550		
		51	Ferns, G. A. A. et al., "Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF," Science, 1991, 253, 1129-1132		
		52	Fischman, D. L. et al., "A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease," N. Eng. J. Med., 1994 Aug 25, 331(8), 496-501		
		53	Franklin, S. M. et al., "Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trials," Coron Artery Dis. 1993 Mar, 4(3), 232-242		
<u>.</u>		54		nilast suppresses the vascular fed on a high-cholesterol die	
		55	Guyton, J. R. et al., "Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin," Circ. Res., 1980, 46, 625-634		
		56	Hanson, S. R. et al., "Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone," Proc. Natl. Acad. Sci. USA, 1988, 85, 3184-3188		
		57	Hansson, G. K. et al., "In 1991, 84, 1266-1272	terferon-γ Inhibits Arterial S	tenosis After Injury," Circ.,
/CH		58		apamycin," European Journa	isomerase I Poisons and the 1 of Cancer, Pergamon Press

EXAMINER	/Casey Hagopian/	DATE CONSIDERED	08/19/2007
	<del></del>		

Form	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce		Docket No. CRD5068USNP	Application No. 10/796,397			
			Applicant Robert Falotico, et al.				
			Filing Date March 9, 2004	Group 1615			
			Confirmation No. 1881				
NON	-PAT	ENT DOCUMENTS (In	cluding Author, Title, Date,	Pertinent Pages, Etc.)			
/CH/	59		osporin A inhibits smooth mary," Proc. Natl., Acad. Sci., 1				
	60			me on whole-cell Ca2+ channel 'J Physiol. 1991 Feb, 433, 1-24			
	61	Lang, R. J. et al., "Effects of okadaic acid and ATP gamma S on cell length and Ca(2+)-channel currents recorded in single smooth muscle cells of the guinea-pig taenia caeci.,", Br. J. Pharmacol., 1991 Oct, 104(2), 331-336					
	62	Liu, M. W. et al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit," Circ., 1990, 81, 1089-1093					
	63	Lundergan, C. F. et al., "Terbinafine inhibits the mitogenic response to platelet- derived growth factor in vitro and neointimal proliferation in vivo," Am. J. Cardiol., 1991, 17(Suppl. B), 132B-136B					
	64	Majesky, M. W. et al., "I rat carotid artery," Circ.		scle S phase entry in the injured			
	65	Mak, K-H. et al., "Clinical trials to prevent restenosis after percutaneous coronary revascularization," Ann N Y Acad Sci., 1997 Apr 15, 811, 255-84; discussion 284-8. Review					
	66	Marx, S. O. et al., "Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells," Circ. Res., 1995, 76, 412-417					
	67	Mintz, G. S. et al., "Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study," Circulation. 1996 Jul 1, 94(1), 35-43					
1	68	Mintz, G. S. et al., "Axial plaque redistribution as a mechanism of percutaneous transluminal coronary angioplasty," Am J Cardiol, 1996 Feb 15, 77(5), 427-430					
/CH/	69 Mintz, G. S. et al., "Intravascular Ultrasound Assessment of the Mechanisms and						

EXAMINER	/Casey Hagopian/	DATE CONSIDERED	08/19/2007
			C 2004 11/11/

For	rm PT(	0-1449 Modified	Docket No. CRD5068USNP . Application No. 10/796,397					
	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Robert Falotico, et al.					
	U.S. Department of Commerce Patent and Trademark Office		Filing Date March 9, 2004	Group 1615				
			Confirmation No. 1881					
N	ON-PAT	TENT DOCUMENTS (I	ncluding Author, Title, I	Date, Pertinent Pages, Etc.)				
/CH/	70		travascular ultrasound find ardiovasc Diagn. 1996 Fel	ings after excimer laser coronary o, 37(2), 113-118				
	71		Mintz, G. S. et al., "Intravascular ultrasound predictors of restenosis after percutaneous transcatheter coronary revascularization," J Am Coll Cardiol, 1996 Jun, 27(7), 1678-87					
	72	Mintz, G. S. et al., "Intravascular ultrasound to discern device-specific effects and mechanisms of restenosis," Am J Cardiol. 1996 Aug 14, 78(3A), 18-22						
	73	distribution in coronary	Mintz, G. S. et al., "Limitations of angiography in the assessment of plaque distribution in coronary artery disease: a systematic study of target lesion eccentricity in 1446 lesions," Circulation. 1996 Mar 1, 93(5), 924-931					
	74	Modern Fluoropolyme 77-87	Modern Fluoropolymers, (J. Scheirs, ed.), John Wiley & Sons, New York, 1997, pp. 77-87					
	75	Derived Growth Factor	Nemecek, G. M. et al., "Terbinafine Inhibits the Mitogenic Response to Platelet- Derived Growth Factor in Vitro and Neoinimal Proliferation in Vivo," J. Pharmacol. Exp. Thera., 1989, 248, 1167-1174					
·	76	Okada, T. et al., "Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation," Neurosurgery, 1989, 25, 92-98						
	77	Popma, J. J. et al, "Atherectomy of right coronary ostial stenoses: initial and long-term results, technical features and histologic findings," Am J Cardiol., 1991 Feb 15; 67(5), 431-433						
. 🗸	78	Popma, J. J. et al., "Adjuncts to thrombolysis for myocardial reperfusion," Ann Intern Med., 1991 Jul 1, 115(1), 34-44						
/CH/	79	Popma, J. J. et al., "Cli Circulation, 1991 Sep,		ter coronary angioplasty,"				

EXAMINER	/Casey Hagopian/	DATE CONSIDERED	08/19/2007

					· · · · · · · · · · · · · · · · · · ·			
Form				cet No. 5068USNP	Application No. 10/796,397			
· · · · · · · · · · · · · · · · · · ·		Applicant Robert Falotico, et al.						
		nent of Commerce Frademark Office		g Date h 9, 2004	Group 1615			
			Conf	irmation No.				
NON	-PAT	ENT DOCUMENTS (Incl	ludin	g Author, Title, Date,	Pertinent Pages, Etc.)			
/CH/	80		r direc		ural correlates of quantitative ctomy," J Am Coll Cardiol.,			
	81	Powell, J. S. et al., "Inhib Myointimal Proliferation						
	82		Serruys, P. W. et al., "A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease," N Engl J Med, 1994 Aug 25; 331(8), 489-495					
	83	Serruys, P. W. et al., "Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial," Circulation. 1993 Oct; 88(4 Pt 1), 1588-1601						
	84		Serruys, P. W. et al., "Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study," Circulation, 1996 Feb 1; 93(3), 412-422					
	85	Serruys, P. W. et al., "Randomized trials of coronary stenting," J Interv Cardiol, 1994 Aug; 7(4), 331						
	86	Serruys, P. W. et al., "Res coronary angiography," A						
	87		Serruys, P. W. et al., "The bailout stent. Is a friend in need always a friend indeed?" Circulation, 1993 Nov; 88(5 Pt 1), 2455-2457					
	88	Seto, S. et al., "Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity to nondividing human lymphocytes," J Clin Invest, 1985 Feb, 75(2), 377-383						
<b>V</b>	89	Simons, M. et al., "Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo," Nature, 1992, 359, 67-70						
/CH/	/CH/ Snow, A. D. et al., "Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth muscle cells," Am. J. Pathol., 1990, 137, 313-330							
EXAMINER	EXAMINER /Casey Hagopian/ DATE CONSIDERED 08/19/2007							

Form	List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce		Docket No. CRD5068USNP	Application No. 10/796,397				
			Applicant Robert Falotico, et al.					
			Filing Date March 9, 2004	Group 1615				
			Confirmation No. 1881					
NON	I-PAT	ENT DOCUMENTS (In	cluding Author, Title, Da	te, Pertinent Pages, Etc.)				
/CH/	91	Sollot, S. J. et al., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat," J. Clin. Invest., 1995, 95, 1869-1876						
	92	Tanaka, H. et al., "Sustained activation of vascular cells and leukocytes in the rabbit aorta after balloon injury," Circulation, 1993 Oct; 88(4 Pt 1), 1788-1803						
	93	Tardif, et al., "Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probucol Study Group," N Engl J Med. 1997 Aug 7; 337(6), 365-372						
	94		Teirstein, P. S. et al., "Catheter-based radiotherapy to inhibit restenosis after coronary stenting," N Engl J Med., 1997 Jun 12; 336(24), 1697-1703					
	95	Weinberger, J. et al., "Intracoronary irradiation: dose response for the prevention of restenosis in swine," Int. J. Rad. Onc. Biol. Phys., 1996, 36, 767-775						
	96	Woo, S. H. et al., "Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors," J. Med Chem, 2002, 45, 2877-2885						
/CH/	97	Yokoi, H. et al., "Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial," J Am Coll Cardiol., 1997 Oct; 30(4), 855-862						

EXAMINER	/Casey Hagopian/	DATE CONSIDERED 08/19/2007



## SUBMISSION UNDER MPEP 609 D

Application Number 10/796,397

Filing Date March 9, 2004

First Named Inventor Robert Falotico

Group Art Unit 1615

Examiner Name C.A. Azpuru

Attorney Docket Number CRD5068USNP

Page 1 of 1

		Page 1 of 1						330000	<del></del>
		U.S. PA	ATE		CUMENTS				
				U.S. P	atent Docume	ent	•		
Examiner	Cite	Name of Patentee or Applicant		Kind Co		nd Code <sup>2</sup>	Code <sup>2</sup> Pages, Columns, Lines, where relevant passages		
Initials	No.1	of Cited Document	- 1	Numb	er	(if	known)	relevant figure	ures appear
	1		_				T	1	
	<del> </del>				<del></del>		<del> </del> -	<del> </del>	
							<u> </u>		
			$\neg$						
	<del> </del>		+				<del> </del>		
	<u> </u>		_				ļ	· · · · · · · · · · · · · · · · · · ·	
								]	
			П						
	t		$\dashv$				<del>                                     </del>		
	┼		-+		•	· · · · · · · · · · · · · · · · · · ·	<del> </del>	<del></del>	
	<u> </u>		_				<u> </u>		
	1	1							
		1							
	1	FOREIGN	I PA	TENT	DOCUMENT	rs			
····	1	l T	For	eign Pa	tent Documer	nt	Pages,	Columns, Lines,	
Examiner	Cite	Name of Patentee or					where relevant passages or relevant figures		ا ــ
Initials	No.1	Applicant of Cited Document	Offi	ice <sup>3</sup>	Number <sup>4</sup> F	CindCode <sup>6</sup>	"."	appear	™
	140.	<u> </u>			<u> </u>	1	<del>                                     </del>		<u> </u>
	<del> </del>	<del>├</del>			<del></del>		<del> </del>		
	ļ					<u> </u>	<u> </u>		
		l				1	l		
	<del>                                     </del>	<u> </u>	_		<del> </del>	<del> </del>	<del> </del>		-
	<b>.</b>				<b></b>	<del> </del>			
	<u> </u>						<u> </u>		
	l			. <b></b>	<i>_</i>		l		
		OTHER PRIOR ART - NO	N P	ATENT	LITERATURI	E DOCUMEN	ITS _		
Examiner	Cite	Include name of the author (in CA title of the Item (book, magazine,	PIT	OL LE	TTERS), title	e of the arti	de (when	appropriate),	T <sup>2</sup>
's	No.1	volume-issue number(s)	jour Jug J	naı, se blisher	mai, sympos , city and/or	country wh	ere publi:	ale, page(s), shed	"
Initials*					-				·
/CH/	<del>                                     </del>	European Search Report re: EP 05 25 13	389 c	dated D	ecember 13, 2	2005			
	<del>                                     </del>								
	<del> </del> -	-					• "	·	
	<del>                                     </del>	†		-					

Examiner   /Casev Hagopian/	Date Considered	08/19/2007